Zoltan Labs | Pipeline

[The proposed human trials are based on the results described in seven issued and three pending U.S. and international patent applications.]

Candidate & Indication

Developmental Stage

Pre-clinical & Animal Toxicology

Human Phase 1 Human Toxicology

Human Phase 2 Clinical

I. rPLAP for treating cancer cachexia and protecting bone marrow function.

Exit after Phase 1 or move to Phase 2

II. rPLAP + chemotherapy for cancer treatments in Phase II trial examining the expected outcomes:
1. Enhance cancer treatments,
2. Reduce muscle wasting,
3. Reduce loss of body weight, and
4. Protect bone marrow

Exit after Phase 2 trial

III. PLAP with or without a statin for the treatment of dyslipidemia